Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EPS (Basic)EPS (Weighted Average and Diluted)Interest & Investment IncomeInterest ExpensesInterest ExpensesNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nautilus Biotechnology (NAUT) Operating Expenses (2020 - 2026)

Nautilus Biotechnology has reported Operating Expenses over the past 7 years, most recently at $16.1 million for Q1 2026.

  • Quarterly results put Operating Expenses at $16.1 million for Q1 2026, down 14.43% from a year ago — trailing twelve months through Mar 2026 was $64.1 million (down 18.54% YoY), and the annual figure for FY2025 was $66.8 million, down 17.97%.
  • Operating Expenses reached $16.1 million in Q1 2026 per NAUT's latest filing, up from $15.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $21.6 million in Q1 2024 and bottomed at $15.4 million in Q4 2025.
  • Median Operating Expenses over the past 5 years was $18.1 million (2023), compared with a mean of $17.9 million.
  • The largest annual shift saw Operating Expenses surged 90.35% in 2022 before it decreased 22.8% in 2025.
  • Over 5 years, Operating Expenses stood at $16.3 million in 2022, then grew by 22.68% to $20.0 million in 2023, then decreased by 0.1% to $20.0 million in 2024, then fell by 22.8% to $15.4 million in 2025, then increased by 4.54% to $16.1 million in 2026.
  • Business Quant data shows Operating Expenses for NAUT at $16.1 million in Q1 2026, $15.4 million in Q4 2025, and $15.5 million in Q3 2025.